Client issue
A leading pharmaceutical company sought CRA Life Sciences experts to gain a deeper understanding of how governments plan and finance national cancer strategies, particularly in light of persistent underfunding and lack of transparency within many National Cancer Control Programs (NCCPs). Although numerous NCCPs exist as policy documents, they often lack dedicated funding and practical costing strategies. The client required an evidence-based, stylized funding framework to support policy dialogues with governments—demonstrating how cost estimates for NCCPs can be effectively determined and funded to transition from aspiration to execution, while aligning with national cancer priorities.
CRA approach
• Conducted a targeted literature review and cross-country analysis of 26 NCCPs across low-, middle-, and high-income countries.
• Examined funding models, policy commitments, and implementation gaps to understand how cancer-control priorities are translated into practice.
• Developed an adaptable, evidence-based costing framework to support more transparent and strategic planning of NCCP activities.
• Applied the framework to illustrative case studies (e.g., HPV vaccination) to highlight common barriers, resource requirements, and potential solutions.
• Developed clear calls to action highlighting the need for dedicated funding, improved costing practices, and accountability mechanisms within national cancer plans.
Client impact
• Delivered strategic insights to support government affairs and policy initiatives across oncology portfolios.
• Enabled proactive engagement with policymakers by highlighting funding and infrastructure gaps that affect access to innovation.
• Positioned the client as a knowledgeable partner in global cancer control, supporting value-based care and equitable access across diverse healthcare systems.
